Open AccessHDAC2/3 inhibitor MI192 mitigates oligodendrocyte loss and reduces microglial activation upon injury: a potential role of epigenetics
Author(s) -
Mohamed A. Al-Griw,
Mansur E Shmela,
Mohamed Elhensheri,
Emad M Bennour
Publication year - 2021
Publication title -
open veterinary journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.39
H-Index - 10
eISSN - 2226-4485
pISSN - 2218-6050
DOI - 10.5455/ovj.2021.v11.i3.18
Subject(s) - microglia , histone deacetylase 2 , oligodendrocyte , epigenetics , white matter , traumatic brain injury , histone deacetylase inhibitor , medicine , apoptosis , pharmacology , histone deacetylase , pathology , biology , neuroscience , histone , myelin , central nervous system , inflammation , biochemistry , radiology , psychiatry , magnetic resonance imaging , gene
During development, oligodendrocyte (OL) lineage cells are susceptible to injury, leading to life-long clinical neurodevelopmental deficits, which lack effective treatments. Drugs targeting epigenetic modifications that inhibit histone deacetylases (HDACs) protect from many clinical neurodegenerative disorders.